Description
Structure & Identity
Retatrutide is a synthetic peptide engineered as a triple receptor agonist. Its backbone is based on the GIP peptide and modified so it can activate the GLP-1, GIP, and glucagon receptors, with a fatty-acid chain attached to extend its lifetime in circulation, as in the other long-acting incretin peptides. There is no single “GLP-3” receptor, despite how the product is sometimes labelled; the “triple” refers to those three distinct receptors.
Research Background
Retatrutide research is about what happens when three metabolic receptors are engaged at once.
- Triple-agonist characterization. It has been described as a GLP-1, GIP, and glucagon receptor agonist, and that three-way action is the core of its research profile [1].
- Metabolic-model studies. Research has examined its effects across metabolic endpoints in study populations [2].
- Liver-focused research. It has also been studied in the context of metabolic dysfunction-associated steatotic liver disease models [3].
These are research contexts, not approved uses, and the peptide is intended purely for laboratory study.
Specifications
| Attribute | Value |
| Chemical name | Retatrutide |
| Also Known As | (GLP-1/GIP/glucagon triple agonist) |
| CAS number | 2381089-83-2 |
| Molecular weight | ~4731 g/mol |
| Purity | ≥99% by reverse-phase HPLC |
| Length | LY3437943 |
| Identity | Confirmed by ESI mass spectrometry |
| Physical form | Lyophilized powder |
| Appearance | White to off-white solid |
| Quantity | 10 mg per vial |
| Storage | -20°C, protected from light |
| Solubility | Soluble in bacteriostatic or sterile water (gentle mixing) |
| Classification | Research use only |
Storage & Handling
Keep the sealed vial frozen at -20°C and shielded from light until you use it. After reconstitution, store the solution at 2-8°C and use it within about two weeks. As a large modified peptide, Retatrutide is best warmed to room temperature before opening and divided into aliquots so it is not frozen and thawed repeatedly.
Quality Assurance
Retatrutide is produced under research-grade manufacturing controls and released only after an outside lab has verified it. Purity is measured by reverse-phase HPLC and identity by mass spectrometry, with that testing carried out by independent third-party laboratories, including Janoshik Analytical and domestic US labs. A certificate of analysis is issued for each batch, so its figures match the exact vial you receive.
Frequently Asked Questions
What is Retatrutide?
Retatrutide is a synthetic peptide that acts as a triple agonist at the GLP-1, GIP, and glucagon receptors. It is studied in metabolic and incretin research and is supplied for research use only.
What does “triple agonist” mean?
It means one molecule that activates three different receptors. Retatrutide engages the GLP-1, GIP, and glucagon receptors, compared with the single- and dual-receptor incretin peptides.
Is there really a “GLP-3” receptor?
No, Retatrutide is a GLP-1 / GIP / glucagon triple agonist. There is no GLP-3 receptor.
How is Retatrutide different from Tirzepatide?
Tirzepatide is a dual agonist (GIP and GLP-1). Retatrutide adds a third target, the glucagon receptor, making it a triple agonist. That extra receptor is the key difference.
Is Retatrutide FDA approved?
No, Retatrutide is an investigational compound and is not FDA approved. The material sold here is a research-use-only reference peptide, not for human or veterinary use.
Why are the CAS number and molecular weight marked “confirm”?
Retatrutide is a newer compound, and its registry identifiers are not consistently reported yet. We flag those fields so they can be verified against an authoritative source before publishing.
Why choose the 10 mg size?
The 10 mg vial suits standard research quantities. The amount refers to the Retatrutide peptide content.
How should Retatrutide be stored?
Keep the powder frozen at -20°C and protected from light. Once reconstituted for research, store the solution at 2-8°C and use within about two weeks.
How is this Retatrutide verified?
It is tested to ≥99% purity by reverse-phase HPLC with mass-spec identity confirmation by an independent lab, and each batch ships with its own certificate of analysis.
References
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. 2023. PMID: 37366315.
- Efficacy and safety of Retatrutide, a GIP, GLP-1, and glucagon receptor agonist. 2026. PMID: 42250575.
- Triple hormone receptor agonist Retatrutide for metabolic dysfunction-associated steatotic liver disease. 2024. PMID: 38858523.
